These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 19336749)

  • 1. Therapy-related myeloid neoplasms.
    Larson RA
    Haematologica; 2009 Apr; 94(4):454-9. PubMed ID: 19336749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inclusion of secondary chronic myelomonocytic leukemia and myeloproliferative disease, unclassifiable, in classification of pediatric myeloproliferative disorders.
    Occhipinti E; Correa H; Yu L; Craver R
    J Pediatr Hematol Oncol; 2006 Oct; 28(10):700-1. PubMed ID: 17023836
    [No Abstract]   [Full Text] [Related]  

  • 3. Second malignancies after chemotherapy and transplantation.
    Gertz MA; Noël P; Kyle RA
    Crit Rev Oncol Hematol; 1993 Apr; 14(2):107-25. PubMed ID: 8357510
    [No Abstract]   [Full Text] [Related]  

  • 4. Therapy-related myeloid neoplasms in lymphoma survivors: Reducing risks.
    Al-Juhaishi T; Khurana A; Shafer D
    Best Pract Res Clin Haematol; 2019 Mar; 32(1):47-53. PubMed ID: 30927975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myeloid neoplasms secondary to plasma cell myeloma: an intrinsic predisposition or therapy-related phenomenon? A clinicopathologic study of 41 cases and correlation of cytogenetic features with treatment regimens.
    Reddi DM; Lu CM; Fedoriw G; Liu YC; Wang FF; Ely S; Boswell EL; Louissaint A; Arcasoy MO; Goodman BK; Wang E
    Am J Clin Pathol; 2012 Dec; 138(6):855-66. PubMed ID: 23161720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secondary acute myeloid leukemia in children previously treated with alkylating agents, intercalating topoisomerase II inhibitors, and irradiation.
    Sandoval C; Pui CH; Bowman LC; Heaton D; Hurwitz CA; Raimondi SC; Behm FG; Head DR
    J Clin Oncol; 1993 Jun; 11(6):1039-45. PubMed ID: 8388919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How much does 2016 WHO classification of myeloproliferative neoplasms affect the clinic?
    Cassinat B; Giraudier S; Kiladjian JJ
    Expert Rev Hematol; 2019 Jul; 12(7):473-476. PubMed ID: 31161817
    [No Abstract]   [Full Text] [Related]  

  • 8. Characteristics and outcomes of therapy-related myeloid neoplasms after treatment for multiple myeloma.
    Duong VH; Holtzman NG; Koka R; Singh ZN; Zou Y; Emadi A; Rapoport AP; Kocoglu MH; Baer MR; Badros AZ
    Leuk Lymphoma; 2019 Dec; 60(14):3577-3580. PubMed ID: 31282234
    [No Abstract]   [Full Text] [Related]  

  • 9. TP53 and therapy-related myeloid neoplasms.
    Chung J; Sallman DA; Padron E
    Best Pract Res Clin Haematol; 2019 Mar; 32(1):98-103. PubMed ID: 30927980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapy-related myeloid neoplasms].
    Harada Y; Harada H
    Nihon Rinsho; 2012 Apr; 70 Suppl 2():699-703. PubMed ID: 23134031
    [No Abstract]   [Full Text] [Related]  

  • 11. Therapy-Related Myeloid Neoplasms.
    Bueso-Ramos CE; Kanagal-Shamanna R; Routbort MJ; Hanson CA
    Am J Clin Pathol; 2015 Aug; 144(2):207-18. PubMed ID: 26185306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survivors of childhood cancer and risk of a second tumor.
    Robison LL
    J Natl Cancer Inst; 1993 Jul; 85(14):1102-3. PubMed ID: 8320735
    [No Abstract]   [Full Text] [Related]  

  • 13. Myelodysplasia and acute leukemia after autologous bone marrow transplantation.
    Armitage JO
    J Clin Oncol; 2000 Mar; 18(5):945-6. PubMed ID: 10694542
    [No Abstract]   [Full Text] [Related]  

  • 14. Myeloid leukemia after cytotoxic therapy and other hematotoxins.
    Larson RA
    J Toxicol Environ Health A; 2000 Nov; 61(5-6):381-6. PubMed ID: 11086943
    [No Abstract]   [Full Text] [Related]  

  • 15. Molecular and cytogenetic characteristics of myeloid malignancies following luminal gastrointestinal cancer.
    Epstein-Peterson ZD; Devlin SM; Stein EM; Klimek VM; Saltz LB; Tallman MS
    Leuk Res; 2019 Jul; 82():19-23. PubMed ID: 31151028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Translocation (3;21)(q26;q22) in therapy-related myelodysplasia following drugs targeting DNA-topoisomerase II combined with alkylating agents, and in myeloproliferative disorders undergoing spontaneous leukemic transformation.
    Pedersen-Bjergaard J; Johansson B; Philip P
    Cancer Genet Cytogenet; 1994 Aug; 76(1):50-5. PubMed ID: 8076352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myelodysplastic syndromes complicating hematopoietic stem cell transplantation.
    Fassas AB; Tricot G
    Cancer Treat Res; 2001; 108():169-84. PubMed ID: 11702599
    [No Abstract]   [Full Text] [Related]  

  • 18. Poly(ADP-ribose)polymerase inhibitors-associated myeloid neoplasms: a retrospective study from the French Network of Pharmacovigilance centres.
    Morice PM; Genthon A; Boyer T; Bihan K; Mahé J; Sourisseau A; Peyrouzet H; Miremont G; Lepelley M; Stefani L; Gaboriau L; Rocher F; Aquaronne D; Le Beller C; Allouchery M; Azzouz B; Massy N; Alt-Tebacher M; Simand C; Herbrecht R; Chrétien B; Dolladille C; Chantepie S; Alexandre J
    Br J Haematol; 2022 Feb; 196(3):787-793. PubMed ID: 34611896
    [No Abstract]   [Full Text] [Related]  

  • 19. Hodgkin's disease, splenectomy and secondary leukemia.
    Centurioni R; Brianzoni F; Leoni P; Danieli G
    Haematologica; 1993; 78(4):258-9. PubMed ID: 8294062
    [No Abstract]   [Full Text] [Related]  

  • 20. Preface.
    Michaelis LC
    Best Pract Res Clin Haematol; 2019 Mar; 32(1):1-2. PubMed ID: 30927968
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.